NASDAQ · EPRX
Healthcare · Biotechnology
$6.85
Up+$0.03 (+0.44%)
Updated Aug 19, 2026, 9:41 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
EPRX closed at $6.85 after 21 trading sessions, up 7.37% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $6.81 | $6.88 | $6.715 | $6.85 | 379.17K |
| Aug 17, 2026 | $6.72 | $6.89 | $6.65 | $6.82 | 127.28K |
| Aug 14, 2026 | $6.66 | $6.72 | $6.46 | $6.72 | 164.66K |
| Aug 13, 2026 | $6.70 | $6.87 | $6.495 | $6.67 | 255.9K |
| Aug 12, 2026 | $6.79 | $6.79 | $6.41 | $6.48 | 220.93K |
| Aug 11, 2026 | $6.67 | $6.86 | $6.66 | $6.70 | 181.02K |
| Aug 10, 2026 | $6.77 | $6.885 | $6.66 | $6.66 | 270.22K |
| Aug 7, 2026 | $6.84 | $6.87 | $6.57 | $6.77 | 475.86K |
| Aug 6, 2026 | $6.43 | $6.71 | $6.40 | $6.66 | 199.72K |
| Aug 5, 2026 | $6.57 | $6.70 | $6.44 | $6.48 | 100.39K |
| Aug 4, 2026 | $6.40 | $6.645 | $6.36 | $6.52 | 258.77K |
| Aug 3, 2026 | $6.40 | $6.68 | $6.325 | $6.51 | 98.46K |
| Jul 31, 2026 | $6.55 | $6.74 | $6.15 | $6.40 | 457.16K |
| Jul 30, 2026 | $6.01 | $6.60 | $5.975 | $6.55 | 1.1M |
| Jul 29, 2026 | $6.10 | $6.25 | $5.79 | $5.97 | 784.95K |
| Jul 28, 2026 | $6.13 | $6.24 | $5.92 | $6.10 | 511.79K |
| Jul 27, 2026 | $5.86 | $6.28 | $5.76 | $6.17 | 326.17K |
| Jul 24, 2026 | $6.37 | $6.37 | $5.72 | $5.81 | 892.5K |
| Jul 23, 2026 | $6.40 | $6.42 | $6.18 | $6.30 | 192.67K |
| Jul 22, 2026 | $6.44 | $6.83 | $6.395 | $6.42 | 901.7K |
| Jul 21, 2026 | $6.32 | $6.57 | $6.1809 | $6.38 | 114.38K |
The latest Smart Investors Daily articles mentioning EPRX.
EPRX research
Company profile and research snapshot.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 21, 2026 | RAYMOND JAMES LTD. | Strong Buy | — |
| May 12, 2026 | WILLIAM BLAIR & COMPANY | Outperform | — |
| May 4, 2026 | LEEDE JONES GABLE | Buy | — |
| May 3, 2026 | RESEARCH CAPITAL CORPORATION | Buy | — |
| Jan 8, 2026 | RESEARCH CAPITAL CORPORATION | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last
Benzinga · Jun 26, 2026
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
Benzinga · May 5, 2026
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local,
Benzinga · May 4, 2026
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EPRX.
